Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 2Breast Neoplasms 2Overweight 1Obesity 1Melanoma 1Kidney Neoplasms 1Glioma 1Glioblastoma 1Carcinoma, Lobular 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Tamoxifen 10Specimen Handling 5Chemotherapy, Adjuvant 5Radiotherapy 3Mastectomy, Segmental 3Anastrozole 3Simvastatin 2telapristone acetate 1ruxolitinib 1exemestane 1abemaciclib 1Vinorelbine 1Trastuzumab 1Telemedicine 1Tablets 1Surgical Procedures, Operative 1Sugars 1Starch 1Soybean Proteins 1Radiation Dose Hypofractionation 1Radiation 1Protons 1Proton Therapy 1Probiotics 1Pharmacogenomic Testing 1Omacor 1Neoadjuvant Therapy 1Naltrexone 1Mastectomy, Subcutaneous 1Lovastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Breast Carcinoma In Situ × Naltrexone × Clear all
NCT02137252 2021-11-16

Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Terminated
3 enrolled 4 charts
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡